When Hitting the Target Isn't Enough: What LUMA Tells Us About Parkinson's Drug Development

BIIB122 missed every endpoint despite >90% peripheral kinase inhibition. The reasons matter for the LRRK2 hypothesis, for the Ionis ASO that worked better, and for where PD drug development goes next